Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/20
End: 08/31/24
Due: 08/31/25
Phase: N/A
Priority: Normal
Start: 04/02/24
End: 01/31/27
Due: 01/31/28
Phase: N/A
Priority: Normal
Start: 09/16/15
End: 11/13/15
Due: 11/13/16
Phase: N/A
Priority: Normal
Start: 09/26/15
End: 07/04/16
Due: 07/04/17
Phase: N/A
Priority: Normal
Start: 05/19/21
End: 07/29/24
Due: 07/29/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease | NCT04693520 | Alzheon Inc. | user2@example.com | None | 2020-09-30 | 2024-08-31 | 2025-08-31 | - | - | 2025-07-14 |
| Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects | NCT06304883 | Alzheon Inc. | user2@example.com | None | 2024-04-02 | 2027-01-31 | 2028-01-31 | - | - | 2025-07-14 |
| Single Dose Study of ALZ-801 Prototype Tablets | NCT04585347 | Alzheon Inc. | user2@example.com | None | 2015-09-16 | 2015-11-13 | 2016-11-13 | - | - | 2025-07-14 |
| Multiple Ascending Dose Study of ALZ-801 | NCT04157712 | Alzheon Inc. | user2@example.com | None | 2015-09-26 | 2016-07-04 | 2017-07-04 | - | - | 2025-07-14 |
| An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects | NCT04770220 | Alzheon Inc. | user2@example.com | None | 2021-05-19 | 2024-07-29 | 2025-07-29 | - | - | 2025-07-14 |